Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by wofatson Apr 16, 2023 7:55pm
208 Views
Post# 35397655

RE:Markets move higher while GUD & Mugsy bite the dust

RE:Markets move higher while GUD & Mugsy bite the dust

Have a look at the new investor presentation and it may shed some light on what you asked about the decline.
Things have changed in the product pipeline. Increased sales will come this year from the new drug approvals .I count 17 new revenue streams. I think I am close.  
Sales should be excellent. 320-340 ish?
Processes should help strengthen margins .
The market looks to be improving .
They do need some additional  advisors to pick up coverage on the stock in my opinion. None of the public  has a clue what Knight is or what it does . The forecasts that the current group give are not even close .
The current price is cheap. It does take a strong stomach to add. 
Insiders are actively buying and buy backs look to be continuing.
First quarter is done and should point the way we go. Earning should be out in the next 3 weeks.
Thats all I've got.

 



Time will tell.

https://www.gud-knight.com/wp-content/uploads/GUD-Fact-Sheet-1-2-23.pdf

<< Previous
Bullboard Posts
Next >>